|
Ro52 epitopes
| |
Ro52 peptides
|
---|
|
1
|
2
|
3
|
4
|
5
|
Full-length Ro52
|
200–239 aa
|
175–196 aa
|
---|
Total SARDs (n = 100)
|
3 (3 %)
|
97 (97 %)
|
0
|
9 (9 %)
|
28 (28 %)
|
100 (100 %)
|
74 (74 %)
|
6 (6 %)
|
MCTD (n = 7)
|
0
|
7 (100 %)
|
0
|
0
|
2 (29 %)
|
7 (100 %)
|
5 (71 %)
|
0
|
Myositis (n = 27)
|
1 (4 %)
|
24 (89 %)
|
0
|
3 (11 %)
|
5 (19 %)
|
27 (100 %)
|
16 (59 %)
|
1 (4 %)
|
RA (n = 7)
|
0
|
7 (100 %)
|
0
|
0
|
2 (29 %)
|
7 (100 %)
|
5 (71 %)
|
0
|
SLE (n = 23)
|
1 (4 %)
|
23 (100 %)
|
0
|
1 (4 %)
|
6 (26 %)
|
23 (100 %)
|
19 (83 %)
|
2 (8 %)
|
SjS (n = 34)
|
1 (3 %)
|
34 (100 %)
|
0
|
5 (15 %)
|
13 (38 %)
|
34 (100 %)
|
28 (82 %)
|
3 (9 %)
|
SSc (n = 2)
|
0
|
2 (100 %)
|
0
|
0
|
0
|
2 (100 %)
|
1 (50 %)
|
0
|
Controls (n = 68)
|
0
|
0
|
0
|
0
|
0
|
0
|
1 (1 %)
|
1 (1 %)
|
-
MCTD Mixed connective tissue disease, SLE systemic lupus erythematosus, RA rheumatoid arthritis, SSc systemic sclerosis, SjS Sjögren’s syndrome, aa amino acid, SARD systemic autoimmune rheumatic disease
- Data are presented as number (%)